药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tazarotene
Sparfloxacin
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Sparfloxacin.
Tazarotene
Domperidone
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Domperidone.
Tazarotene
Escitalopram
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Escitalopram.
Tazarotene
Relugolix
The risk or severity of QTc prolongation can be increased when Relugolix is combined with Arsenic trioxide.
Tazarotene
Fostemsavir
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Arsenic trioxide.
Tazarotene
Aripiprazole lauroxil
The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Arsenic trioxide.
Tazarotene
Ebastine
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Arsenic trioxide.
Tazarotene
Lurasidone
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Arsenic trioxide.
Tazarotene
Aripiprazole
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Arsenic trioxide.
Tazarotene
Cilostazol
The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Arsenic trioxide.
Tazarotene
Digitoxin
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Digitoxin.
Tazarotene
Rilpivirine
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Arsenic trioxide.
Tazarotene
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Arsenic trioxide.
Tazarotene
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Arsenic trioxide.
Tazarotene
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Arsenic trioxide.
Tazarotene
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Arsenic trioxide.
Tazarotene
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Arsenic trioxide.
Tazarotene
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Arsenic trioxide.
Tazarotene
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Arsenic trioxide.
Tazarotene
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Arsenic trioxide.